ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / NRXS
STXS (22) VANI (28) HYPR (38) OM (34) ⌘ Pro Terminal β†’

Neuraxis Inc. (NRXS) β€” RQD Stock Rating Cockpit

$6.60 -7.43% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.50

Neuraxis Inc. (NRXS) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $89.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NRXS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is NRXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Neuraxis Inc. (NYSE: NRXS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $6.60 (-7.43% 1D, market cap $89.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NRXS ranks #569 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does NRXS compare to STXS and VANI in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NRXS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 84.2%, and ROIC of -35.0%. By comparison, STXS (Stereotaxis Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $86.4M) and VANI (Vivani Medical Inc.) posts a E grade (28/100 RQD, P/E 3.9x, ROIC -35.0%, cap $98.3M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NRXS?
β–Ό

Per NRXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001933567), Neuraxis Inc. generated $3.6M in revenue (+32.9% YoY), -$7.8M in net income, and -$6.5M in free cash flow against $6.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.50 (-1.53%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (36/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (5)Whales (10)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
$10 Bull$6 Base$5 Bear
πŸ“¬ FREE NRXS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for NRXS)Realized 20D OHLCV Swing Band: Β±12.2%
Deterministic 5-Pillar Attribution (36/100 Composite)
πŸ” WHY NRXS SCORES 36/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+10/20 pts (28% of score)

20D Institutional Volume Accumulation (Β±12.2% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 1.88 (WATCH ZONE (1.8–3.0)) β€’ Piotroski F-Score 5/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
28
Grade E$6.50+20.3% Next Q
Q2 (-2Q)
31
Grade E$7.82-5.9% Next Q
Q3 (-1Q)
33
Grade E$7.36-10.3% Next Q
Current
36
Grade D-$6.60-8.3% Hist 90D Ξ±
Trajectory: E (28) β†’ D- (36)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a NRXS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While NRXS currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.88) and Max Pain ($6.93) forces dealer call-delta covering toward $9.80.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRXSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œNRXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
4830 Oversold Β· 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
1.88>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE62% OF RANGE
L: $2$6.60H: $9
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on NRXS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-35.0% ROIC with 84.2% gross margin and -6.82% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 1.88 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (35)

13/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like NRXS
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRXS)

  • βœ“Walkthrough of NRXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
NRXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.48%πŸ“ HORIZONTAL RANGE
2026-11-03O $7.55H $7.55L $6.60C $6.60VOL 150.4K
RES: $8.43SUP: $4.29SMA50: $6.88SMA200: $6.69
$9.69$8.19$6.68$5.18$3.67RES $8.43SUP $4.29$6.602026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ NRXS Butterfly Map β†’ + Track NRXS β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +32.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NRXS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for NRXS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NRXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRXS)

Health Care Rank #569 of 1015 βš”οΈ STXS vs NRXS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (NRXS vs. STXS, VANI, HYPR, OM)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Neuraxis Inc. (NRXS) ranks #569 by composite RQD confidence (36/100, grade D-) and #667 by equity capitalization ($89.5M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with NRXS at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NRXS ACTIVE
Neuraxis Inc.
D- 36/100 β€” 84.2% -35.0% -7.43% $89.5M Benchmark Subject
STXS
Stereotaxis Inc.
E 22/100 β€” 52.7% -35.0% +2.03% $86.4M /stxs-vs-nrxs β†’
VANI
Vivani Medical Inc.
E 28/100 3.9x β€” -35.0% 0.00% $98.3M /vani-vs-nrxs β†’
HYPR
Hyperfine Inc. (Class A)
D- 38/100 β€” 49.8% -35.0% +0.99% $76.1M /hypr-vs-nrxs β†’
OM
Outset Medical Inc.
E 34/100 β€” 39.1% -28.0% -0.25% $75.8M /om-vs-nrxs β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001933567 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuraxis Inc. (NRXS) reported GAAP revenue of $3.6M (+32.9% vs. FY2024 revenue of $2.7M , and +45.1% cumulative change since FY2023) , GAAP net income of -$7.8M, operating cash flow of -$6.4M, and free cash flow of -$6.5M (-5.5% YoY). On the balance sheet, NRXS closed FY2025 with $6.4M in total assets against $0 in total debt (Altman Z-Score: 1.88, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.6M -$7.8M -$6.4M -$6.5M $6.4M β€”
FY2024 (FY) 2024-12-31 $2.7M -$8.2M -$6.1M -$6.1M $4.8M β€”
FY2023 (FY) 2023-12-31 $2.5M -$14.6M -$6.7M -$6.7M β€” β€”

3. NRXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Neuraxis Inc. (NYSE: NRXS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $6.60 (-7.43% 1D, market cap $89.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NRXS ranks #569 in composite RQD confidence.

How does NRXS compare to STXS and VANI in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NRXS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 84.2%, and ROIC of -35.0%. By comparison, STXS (Stereotaxis Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $86.4M) and VANI (Vivani Medical Inc.) posts a E grade (28/100 RQD, P/E 3.9x, ROIC -35.0%, cap $98.3M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NRXS?

Per NRXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001933567), Neuraxis Inc. generated $3.6M in revenue (+32.9% YoY), -$7.8M in net income, and -$6.5M in free cash flow against $6.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NRXS trading relative to its 50-day, 200-day, and 52-week technical levels?

NRXS last traded at $6.60 (-7.43% on volume of 125,734 shares), positioning the stock -4.07% below its 50-day simple moving average ($6.88) and -1.35% below its 200-day simple moving average ($6.69). Across its 52-week range of $2.21 to $9.33, NRXS sits at the 61.7% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.2% ($5.79 to $7.41).

Direct Sub-Reports: NRXS RQD Cockpit NRXS 12M Forecast NRXS Earnings & Move NRXS Dividends & DRIP NRXS Insiders & 13F NRXS Whale Options NRXS Profit Sankey NRXS News & Why
ROARABLE RATING BRIEF β€’ RQD 36/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

NRXS β€” Neuraxis Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Neuraxis Inc. (NRXS) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.60 (-7.43% 1D, market capitalization $89.5M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 84.2%, operating margin of -60.0%, and free cash flow yield of -6.82%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.88, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Neuraxis Inc. Is a NYSE-listed company classified in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. It operates in this electromedical niche with a market capitalization of $0.1B. FY 2025 revenue was $3.6M, indicating a small revenue base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Neuraxis Inc. (NRXS) reported $3.6M in annual revenue (up from $2.7M in FY2024, +32.9% YoY) and -$7.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.5M revenue, -$14.6M net income) through FY2025, NRXS scaled operating cash flow to -$6.4M and free cash flow to -$6.5M, backed by $6.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.82% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $2.21 – $9.33 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Accordingly, no upstream or downstream dependencies or sector-correlation links are available in source data. A prospective investor should note that coverage expansions and reimbursement-related milestones in the news feed could create second-order effects on revenue scaling, but the graph does not map these to specific suppliers, customers, or peers.

  • Key Question #1: Can NRXS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.6M and free cash flow of -$6.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NRXS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NRXS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neuraxis Inc. (NRXS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to NRXS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NRXS Bull vs. Bear Conversation Board β€” What's Your Call at $6.60?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NRXS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NRXS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $8.48 (+18.9%)
πŸ“Œ Pinned Debate

Revenue grew from $2.5M in FY 2023 to $3.6M in FY 2025 while cash rose from $3.7M to $5.0M, and the whale/13F flow pillar scored 13 of

Don't sleep on NRXS's setup in Health Care. Revenue grew from $2.5M in FY 2023 to $3.6M in FY 2025 while cash rose from $3.7M to $5.0M, and the whale/13F flow pillar scored 13 of 20.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (36/100) backs up the fundamental quality.

VolSurface_Trader πŸ‚ BULL

Both sides have a point here β€” NRXS's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER β€’ Accounting Quality Watch 🐻 BEARISH 🎯 Target: $5.78 (-18.9%)
Spot @ $7.13

Operating margin of -60% and ROIC of -35% against negative free cash flow in every reported year leave the fundamental cash engine scor

Here is the bear case nobody on the bull side wants to address on NRXS: Operating margin of -60% and ROIC of -35% against negative free cash flow in every reported year leave the fundamental cash engine scoring only 5 of 20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Electromedical & Electrotherapeutic Apparatus triggers a 12-15% air pocket.

LIVE TAPE